0853 GMT - GSK has released promising data for its drug candidate mo-rez in gynecological cancers that point to another oncology arrow in the U.K. drugmaker's quiver, Jefferies analysts say in a research note. While the drug showed efficacy for ovarian and endometrial cancers with no major safety red flags in early-stage studies, there are caveats about small sample sizes and slightly different prior lines of therapy, Jefferies says. "Ultimately, the key will be demonstrating that this translates to better clinical efficacy--progression-free survival and overall survival benefits--in later-stage studies," the analysts say. Shares fall 0.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 13, 2026 04:54 ET (08:54 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.